Therapeutic control of hyperlipidemia in the prevention of XXXX : a review of results from recent clinical trials.

@entity1 @entity753 @entity1007 @entity301 @entity731 @entity1670 @entity453 @entity65 @entity165
The link between elevated plasma @entity165 levels and @entity453 is now well established. During the past decade, results from therapeutic trials indicate that control of @entity1007 does result in lower cardiovascular risk. Many of these results were obtained in @entity753 , middle-aged @entity1 . Comparable data in @entity1 are not available but it is inferred that they would also benefit from @entity165 reduction. Results from the Coronary Drug Project, extended over 15 years, indicate that lipid-lowering therapy with @entity1670 for 5 years was associated with a decrease in total mortality as well as mortality from @entity301 . In the studies performed for shorter periods (5 to 7 years), therapy lowered only @entity65 and mortality but had no beneficial effect on total mortality. A reduction in cardiovascular risk begins to appear 24 to 28 months after the initiation of therapy and continues to accrue thereafter. The relatively uniform results from recent large-scale clinical trials (Lipid Research Clinics Coronary Primary Prevention Trial, Coronary Drug Project, Helsinki Heart Study) indicate that @entity165 reduction, per se, probably explains the lower @entity65 and mortality observed in these trials. As a result of these trials, recent redefinitions of @entity1007 and more aggressive treatment programs have been recommended. These guidelines stress assessment of all cardiovascular risk factors and recommend individualized care of the @entity1 . To control @entity1007 , conservative measures with diet are recommended before therapy with medication is considered. Recent clinical trial experience indicates that the clinician can have significant impact on @entity731 by identifying and treating @entity1 with plasma @entity165 levels in the high-risk range.
